Not Signed In -
Cefuroxime Sodium Injection |
Kefurox; Zinacef |
Clinical Trial: Study Conducted in China of the Efficacy and Safety of Enteric-Coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult De Novo Renal Transplant Patients
This study is currently recruiting patients.
Verified by Novartis September 2005
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Renal transplant | Drug: Mycophenolate sodium (enteric coated) | Phase III |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Multicenter, Double-Blind, Randomized, Parallel Group Study on Efficacy and Safety of Enteric-Coated Mycophenolate Sodium Vs. Mycophenolate Mofetil in De Novo Chinese Renal Transplant Recipients
Study start: January 2005
Eligibility
Inclusion Criteria:
-Recipients of first, cadaveric (with donor written consent form) or living related non-HLA identical donor kidney transplant, treated with cyclosporine and corticosteroids as primary immunosuppression.
Exclusion Criteria:
- Second or subsequent kidney transplant or multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any other organ
- Patients who have received an investigational drug within four weeks prior to study entry
Other protocol-defined inclusion/exclusion criteria may apply.
Location and Contact Information
China
General Hospital, Friendship Hospital, Beijing, No 1 Hospital Peking University, Beijing China; Shanghai No 1 Hospital, Shanghai China; Changzheng Hospital, Shanghai, China; Shanghai Ruij, Beijing, China; Recruiting
Novartis, Study Director, Novartis
More Information
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00149903
Health Authority: China: State Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
